From Variation to Convergence: Evolution of Global Regulatory Pathways for Post-Approval CMC Changes and Their Impact on Pharmaceutical Lifecycle Management

Afra P; Hanna Asaraf; Fairoosa Thaikkat

From Variation to Convergence: Evolution of Global Regulatory Pathways for Post-Approval CMC Changes and Their Impact on Pharmaceutical Lifecycle Management

Author(s)	Ms. Afra P, Ms. Hanna Asaraf, Ms. Fairoosa Thaikkat
Country	India
Abstract	Post-approval chemistry, manufacturing and controls (CMC) changes are an integral component of pharmaceutical product lifecycle management. Manufacturing sites, processes, analytical procedures, specifications, equipment, facilities and supply chains may require modification after marketing authorization to accommodate technological improvements, strengthen manufacturing robustness, respond to increased demand, address regulatory requirements, or maintain continuity of supply. However, the regulatory classification, documentation requirements, review procedures and implementation timelines for such changes remain heterogeneous across jurisdictions. This variability can increase regulatory workload and complicate simultaneous global implementation of manufacturing changes. The International Council for Harmonisation (ICH) Q12 guideline introduced a structured framework intended to facilitate more predictable and efficient management of post-approval CMC changes. Its principal regulatory tools include risk-based categorization, Established Conditions (ECs), Post-Approval Change Management Protocols (PACMPs), the Product Lifecycle Management (PLCM) document and integration with the Pharmaceutical Quality System. Nevertheless, evidence from recent international surveys indicates that implementation of these tools remains uneven. Recent studies also demonstrate continuing differences in classification and review timelines among national regulatory authorities. This review critically examines the evolution of post-approval CMC change management and compares regulatory approaches in the European Union, United States, Japan, United Kingdom, Canada and Australia, with additional consideration of World Health Organization (WHO) reliance principles. Particular attention is given to the revised European variations framework, implementation of ICH Q12, regulatory reliance, collaborative assessment and emerging digital approaches to CMC submissions. Published evidence indicates increasing adoption of risk-based approaches but incomplete global convergence. Recent reliance pilots demonstrate the potential to reduce duplicated assessment and improve predictability, while digital dossier initiatives suggest a possible transition toward common-core global submissions. The review proposes that future progress is more likely to result from practical convergence, reliance and structured information exchange than from complete uniformity of national regulatory systems.
Keywords	Post-approval changes; CMC; ICH Q12, regulatory convergence, regulatory reliance, lifecycle management, PACMP, Established Conditions, pharmaceutical regulation, variations
Field	Medical / Pharmacy
Published In	Volume 8, Issue 5, September-October 2026
Published On	2026-09-29

View / Download PDF File

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

From Variation to Convergence: Evolution of Global Regulatory Pathways for Post-Approval CMC Changes and Their Impact on Pharmaceutical Lifecycle Management

Share this